Chest
-
COPD Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: A giant bulla is defined as an air space in the lung that occupies at least 30% of the hemithorax. Indications for surgical resection are controversial but most commonly include dypnea due to compression of adjacent lung tissue or spontaneous pneumothorax. Previous authors have suggested including mediastinal shift as an indication, but outcome data is lacking. We present a unique case of a 71-year-old patient with bullous emphysema which resulted in compression of the dextrocardial structures. ⋯ The following authors have nothing to disclose: B. Jakub Wilhelm, Aniket Sakharpe, Leopoldo Baccaro, Stanley Ogu, Richard AngelicoNo Product/Research Disclosure Information.
-
Tuberculosis PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Tuberculosis (TB) remains a major health concern worldwide. Studies have shown an association between TB and venous thromboembolism (VTE); however, the significance of this association has not been investigated. Despite the increased risk of VTE among patients with TB, to our knowledge, the significance of in-hospital VTE in these patients has not been investigated. We sought to compare the risk factors profile and in-hospital outcomes of hospitalized patients with TB who had coexisting in-hospital VTE versus those who did not have coexisting VTE. ⋯ The following authors have nothing to disclose: Ahmadreza Moradi, Azin Mohebi-Nejad, Seyed-Mohammad Abooturabi, Behzad Yaghoubi, Shahrzad Shemirani, Payam Tabarsi, Neda Behzadnia, Mehdi Esmaili-Khansari, Mohammadreza Masjedi, Ehsan Chitsaz, Behnood Bikdeli, Babak Sharif-KashaniNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Combined use of long-acting bronchodilators with different mechanism of action optimizes bronchodilation and may reduce the risk of exacerbations. QVA149 is a novel dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237) for the maintenance treatment of COPD. Here, we report findings from the SPARK and ILLUMINATE studies of the IGNITE program, with a focus on the rate and prevention of exacerbations. ⋯ Donald Banerji: Employee: Novartis Employee Mark Fedele: Employee: Novartis Employee Hungta Chen: Employee: Novartis EmployeeClinical trial results of QVA149, combination of approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Critical Care Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To determine the characteristics of patients with community-acquired pneumonia and mild acute respiratory distress syndrome (CAP-mild ARDS) who require ICU admission. ⋯ The following authors have nothing to disclose: Laura Novella, Francisco Sanz, Estrella Fernández-Fabrellas, Ángela Cervera, Maria Luisa Briones, María Carmen Aguar, Ruben Lera, Eusebi Chiner, Javier Berraondo, Susana Herrera, Cristina Miralles, Marí Climent, Dolores Martinez, Lucia Gil, José BlanquerNo Product/Research Disclosure Information.
-
ILD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: No published data is available to provide any information about the status of Interstitial Lung Diseases (ILD) in Pakistan. However this study is in continuation of presented data from 2008-11 (Ansarie et al, ERS 2012) to determine the ongoing incidence and relative frequency of various ILDs in Karachi, it's most populous multiethnic city (20 million). ⋯ The following authors have nothing to disclose: Mosavir Ansarie, Asif Naseem, Aneeka Kasmani, Rasheed Ahmed, Muhammad AzeemuddinNo Product/Research Disclosure Information.